When does CNBX stock report earnings and why does it matter?

CNBX stock is scheduled to report earnings on 12 Jan 2026. The report matters because it may disclose cash runway, trial updates for RCC-33 and funding plans—information that can swing this low-priced, high-volume name.

What are the main financial risks for CNBX stock?

Major risks for CNBX stock include negative EPS (**-0.01**), a weak current ratio (**0.0073**), low cash per share (**0.0003204 USD**) and likely dilution if management raises capital to fund trials.

How does Meyka AI view CNBX stock and what is the forecast?

Meyka AI rates CNBX with a score of **67.80** (Grade B, Suggestion: HOLD). Meyka AI's forecast model projects a base-case **$0.0015** in 12 months versus current **$0.0006**. Forecasts are model projections and not guarantees.

What catalysts could move CNBX stock after earnings?

Catalysts include trial progress or positive data for RCC-33, licensing or partnership announcements, clarity on cash runway, and any firm capital raise terms that limit dilution for CNBX stock.

US Stocks

CNBX stock CNBX Pharmaceuticals Inc. (PNK) $0.0006 08 Jan 2026: Earnings on Jan 12 could move value

ByDanny Kontos January 8, 2026January 8, 2026

CNBX stock trades at $0.0006 on the PNK exchange in the United States as of 08 Jan 2026, with volume surging to 114,115,197 shares today. Investors should note an upcoming earnings announcement on 12 Jan 2026, a likely catalyst for this highly volatile name. This earnings spotlight covers price drivers, visible financial stress points such as EPS -0.01 and PE -0.05, and what to watch in the company’s pipeline and liquidity ahead of the print. We focus on clear metrics, short-term triggers, and the forecast that frames risk and reward